Comment on “Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case control study”

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2018.06.043 ◽

2018 ◽

Vol 79 (6) ◽

pp. e111-e112 ◽

Author(s):

Khalaf Kridin

Keyword(s):

Bullous Pemphigoid ◽

Case Control Study ◽

Dipeptidyl Peptidase ◽

Case Control ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitors ◽

Download Full-text

Reply to: “Comment on ‘Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case control study’”

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2018.06.042 ◽

2018 ◽

Vol 79 (6) ◽

pp. e113-e114 ◽

Author(s):

Outi Varpuluoma ◽

Laura Huilaja ◽

Kaisa Tasanen

Keyword(s):

Bullous Pemphigoid ◽

Case Control Study ◽

Dipeptidyl Peptidase ◽

Case Control ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitors ◽

Download Full-text

Oral diabetes medications other than dipeptidyl peptidase 4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2018.05.030 ◽

2018 ◽

Vol 79 (6) ◽

pp. 1034-1038.e5 ◽

Author(s):

Outi Varpuluoma ◽

Anna-Kaisa Försti ◽

Jari Jokelainen ◽

Miia Turpeinen ◽

Markku Timonen ◽

...

Keyword(s):

Bullous Pemphigoid ◽

Case Control Study ◽

Dipeptidyl Peptidase ◽

Case Control ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitors ◽

Download Full-text

Comment on “Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study” and a case report of glucagon-like peptide-1 receptor agonist–induced bullous pemphigoid

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2019.01.086 ◽

2019 ◽

Vol 80 (6) ◽

pp. e189-e190 ◽

Author(s):

Zachary Schwager ◽

Anar Mikailov ◽

Adam D. Lipworth

Keyword(s):

Case Report ◽

Bullous Pemphigoid ◽

Receptor Agonist ◽

Case Control Study ◽

Case Control ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitors ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Download Full-text

Exposure to dipeptidyl‐peptidase‐4 inhibitors and COVID ‐19 among people with type 2 diabetes: A case‐control study

Diabetes Obesity and Metabolism ◽

10.1111/dom.14097 ◽

2020 ◽

Vol 22 (10) ◽

pp. 1946-1950 ◽

Author(s):

Gian Paolo Fadini ◽

Mario Luca Morieri ◽

Enrico Longato ◽

Benedetta Maria Bonora ◽

Silvia Pinelli ◽

...

Keyword(s):

Type 2 Diabetes ◽

Case Control Study ◽

Dipeptidyl Peptidase ◽

Case Control ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitors ◽

Download Full-text

Association Between Use of Dipeptidyl Peptidase-4 Inhibitors and the Risk of Acute Kidney Injury: A Nested Case-Control Study

Mayo Clinic Proceedings ◽

10.1016/j.mayocp.2016.03.022 ◽

2016 ◽

Vol 91 (7) ◽

pp. 867-872 ◽

Author(s):

Chia-Jen Shih ◽

Yi-Jung Lee ◽

Yuan-Hao Lo ◽

Shu-Chen Kuo ◽

Shuo-Ming Ou ◽

...

Keyword(s):

Acute Kidney Injury ◽

Case Control Study ◽

Kidney Injury ◽

Dipeptidyl Peptidase ◽

Case Control ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitors ◽

Nested Case Control ◽

Download Full-text

Reduced incidence of Parkinson's disease after dipeptidyl peptidase-4 inhibitors-A nationwide case-control study

Movement Disorders ◽

10.1002/mds.26734 ◽

2016 ◽

Vol 31 (9) ◽

pp. 1422-1423 ◽

Author(s):

Per Svenningsson ◽

Karin Wirdefeldt ◽

Li Yin ◽

Fang Fang ◽

Ioanna Markaki ◽

...

Keyword(s):

Parkinson’S Disease ◽

Parkinson's Disease ◽

Case Control Study ◽

Dipeptidyl Peptidase ◽

Case Control ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitors ◽

Download Full-text

Reply to: “Comment on ‘Oral diabetes medications other than dipeptidyl peptidase-4 inhibitors are not associated with bullous pemphigoid: A Finnish nationwide case-control study’ and a case report of glucagon-like peptide-1 receptor agonist–induced bullous pemphigoid”

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2019.02.005 ◽

2019 ◽

Vol 80 (6) ◽

pp. e191-e192

Author(s):

Outi Varpuluoma ◽

Kaisa Tasanen ◽

Laura Huilaja

Keyword(s):

Case Report ◽

Bullous Pemphigoid ◽

Receptor Agonist ◽

Case Control Study ◽

Case Control ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitors ◽

Glucagon Like Peptide ◽

Glucagon Like Peptide 1 ◽

Download Full-text

Association Between Pancreatic Cancer and Dipeptidyl Peptidase-4 Inhibitors Use in a Case-Control Study

Mayo Clinic Proceedings ◽

10.1016/j.mayocp.2018.10.001 ◽

2018 ◽

Vol 93 (12) ◽

pp. 1874-1876

Author(s):

Shih-Wei Lai ◽

Cheng-Li Lin ◽

Kuan-Fu Liao

Keyword(s):

Pancreatic Cancer ◽

Case Control Study ◽

Dipeptidyl Peptidase ◽

Case Control ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitors ◽

Download Full-text

Acute Pancreatitis in Patients with Type 2 Diabetes Mellitus Treated with Dipeptidyl Peptidase-4 Inhibitors: A Population-Based Nested Case-Control Study

Drug Safety ◽

10.1007/s40264-014-0171-x ◽

2014 ◽

Vol 37 (7) ◽

pp. 521-528 ◽

Author(s):

Hsin-Chun Chou ◽

Wen-Wen Chen ◽

Fei-Yuan Hsiao

Keyword(s):

Diabetes Mellitus ◽

Type 2 Diabetes ◽

Case Control Study ◽

Population Based ◽

Case Control ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitors ◽

Nested Case Control ◽

Download Full-text

Dipeptidyl peptidase‐4 inhibitor may exacerbate Graves’ disease: a multicenter observational case‐control study

Journal of Diabetes Investigation ◽

10.1111/jdi.13578 ◽

2021 ◽

Author(s):

Tomonori Sekizaki ◽

Hiraku Kameda ◽

Hiroshi Nomoto ◽

Kyu Yong Cho ◽

Akinobu Nakamura ◽

...

Keyword(s):

Case Control Study ◽

Dipeptidyl Peptidase ◽

Case Control ◽

Graves Disease ◽

Dipeptidyl Peptidase 4 ◽

Dipeptidyl Peptidase 4 Inhibitor ◽

Download Full-text